Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure
- 1 May 1994
- journal article
- clinical trial
- Published by Springer Nature in Heart and Vessels
- Vol. 9 (3) , 113-120
- https://doi.org/10.1007/bf01745236
Abstract
The long-term efficacy of the positive inotropic and vasodilator drug, pimobendan, was assessed in 21 patients suffering from symptomatic heart failure. Patients were randomized to 16 weeks of double-blind therapy with either 2.5 or 5.0mg/day of pimobendan (n = 10), or a matching placebo (n = 11). Patients were blinded on the study drug if their clinical status had not substantially worsened during the study. Of the placebo-treated patients, 5 patients were withdrawn from the study because of a deterioration of their heart failure, while none of the active treated group was withdrawn because of increased symptoms. Quality of life, assessed by the specific activity scale derived from the metabolic costs of individual physical activity, was 3.45 ± 0.90 (SD) mets in the baseline state and increased significantly after week 16, averaging 5.07 ± 1.40 and 4.67 ± 1.47 mets at weeks 16 and 24, respectively. In the placebo-treated group, the specific activity scale was 3.27 ± 1.21 mets at the baseline and remained unchanged throughout the study period. Patients treated with pimobendan were able to significantly increase their exercise duration. The accompanying increase in peak oxygen uptake was statistically insignificant, due to the limited number of patients enrolled in the study. These results suggest that in contrast to the recent pessimistic view of the long-term efficacy of cardiotonic drugs, pimobendan is beneficial in treating patients with congestive heart failure and may favorably modify their prognosis. Further largescale evaluation of this agent is warranted.Keywords
This publication has 27 references indexed in Scilit:
- Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathyThe American Journal of Cardiology, 1991
- Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: Long-term effectiveness of add-on therapy with pimobendanAmerican Heart Journal, 1991
- A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failureCardiovascular Drugs and Therapy, 1990
- Post-extrasystolic potentiation and the force-frequency relationship: Differential augmentation of myocardial contractility in working myocardium from patients with end-stage heart failureJournal of Molecular and Cellular Cardiology, 1990
- Cardiovascular Effects and Plasma Level Profile of Pimobendan (UD-CG 115 BS) and Its Metabolite UD-CG 212 in Patients with Congestive Heart Failure After Single and Repeated Oral DosingJournal of Cardiovascular Pharmacology, 1989
- Pimobendan Increases Survival of Cardiomyopathic HamstersJournal of Cardiovascular Pharmacology, 1989
- Calcium-Sensitivity Modulation of Cardiac Myofibrillar ProteinsJournal of Cardiovascular Pharmacology, 1989
- Cellular mechanisms in congestive heart failureThe American Journal of Cardiology, 1988
- I. IntroductionJournal of the American College of Cardiology, 1988
- Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale.Circulation, 1981